Your browser doesn't support javascript.
Potential impact of individual exposure histories to endemic human coronaviruses on age-dependent severity of COVID-19.
Pinotti, Francesco; Wikramaratna, Paul S; Obolski, Uri; Paton, Robert S; Damineli, Daniel S C; Alcantara, Luiz C J; Giovanetti, Marta; Gupta, Sunetra; Lourenço, José.
  • Pinotti F; Department of Zoology, University of Oxford, Oxford, UK. francesco.pinotti@zoo.ox.ac.uk.
  • Wikramaratna PS; Independent Consultant, London, England.
  • Obolski U; School of Public Health, Tel Aviv University, Tel Aviv, Israel.
  • Paton RS; Porter School of the Environment and Earth Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Damineli DSC; Department of Zoology, University of Oxford, Oxford, UK.
  • Alcantara LCJ; Department of Pediatrics, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
  • Giovanetti M; Laboratório de Genética Celular e Molecular, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
  • Gupta S; Laboratório de Flavivírus, Instituto Oswaldo Cruz Fiocruz, Rio de Janeiro, Brazil.
  • Lourenço J; Laboratório de Genética Celular e Molecular, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
BMC Med ; 19(1): 19, 2021 01 12.
Artículo en Inglés | MEDLINE | ID: covidwho-1024366
ABSTRACT

BACKGROUND:

Cross-reactivity to SARS-CoV-2 from exposure to endemic human coronaviruses (eHCoV) is gaining increasing attention as a possible driver of both protection against infection and COVID-19 severity. Here we explore the potential role of cross-reactivity induced by eHCoVs on age-specific COVID-19 severity in a mathematical model of eHCoV and SARS-CoV-2 transmission.

METHODS:

We use an individual-based model, calibrated to prior knowledge of eHCoV dynamics, to fully track individual histories of exposure to eHCoVs. We also model the emergent dynamics of SARS-CoV-2 and the risk of hospitalisation upon infection.

RESULTS:

We hypothesise that primary exposure with any eHCoV confers temporary cross-protection against severe SARS-CoV-2 infection, while life-long re-exposure to the same eHCoV diminishes cross-protection, and increases the potential for disease severity. We show numerically that our proposed mechanism can explain age patterns of COVID-19 hospitalisation in EU/EEA countries and the UK. We further show that some of the observed variation in health care capacity and testing efforts is compatible with country-specific differences in hospitalisation rates under this model.

CONCLUSIONS:

This study provides a "proof of possibility" for certain biological and epidemiological mechanisms that could potentially drive COVID-19-related variation across age groups. Our findings call for further research on the role of cross-reactivity to eHCoVs and highlight data interpretation challenges arising from health care capacity and SARS-CoV-2 testing.
Asunto(s)
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Infecciones por Coronavirus / Reacciones Cruzadas / Protección Cruzada / SARS-CoV-2 / COVID-19 Tipo de estudio: Estudio experimental / Estudio observacional / Estudio pronóstico / Ensayo controlado aleatorizado Tópicos: Vacunas Límite: Humanos Idioma: Inglés Revista: BMC Med Asunto de la revista: Medicina Año: 2021 Tipo del documento: Artículo País de afiliación: S12916-020-01887-1

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Infecciones por Coronavirus / Reacciones Cruzadas / Protección Cruzada / SARS-CoV-2 / COVID-19 Tipo de estudio: Estudio experimental / Estudio observacional / Estudio pronóstico / Ensayo controlado aleatorizado Tópicos: Vacunas Límite: Humanos Idioma: Inglés Revista: BMC Med Asunto de la revista: Medicina Año: 2021 Tipo del documento: Artículo País de afiliación: S12916-020-01887-1